Replies to post #392109 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Missling as far as I can tell hasn’t had too many unchanged views on things like timelines and endpoints, including recently.

[kund]

Here is what Misleading said when Avatar result was released, similar statement after AD result.

https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints

[color=red]Based on the results in this Phase 3 study (ANAVEX®2-73-RS-002)[3] and the prior successful U.S. Phase 2 (ANAVEX®2-73-RS-001)[4] study in adult patients with Rett syndrome, Anavex is planning to meet with FDA to discuss the approval pathway. [/color]There are no FDA-approved drugs for Rett syndrome. ANAVEX®2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome and may be considered for accelerated approval.

[sab63090]

You are sometimes correct, but I think the latest information that Investor proved to you was accurate!

I remembered Missling's statement, it was a fair assessment, based on the Excellence Trial completion date being so close....why not wait for it?

Maybe you should just acknowledge that and stand corrected.